Journal article
Whole blood GRHL2 expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancer
EM Kwan, H Fettke, M Crumbaker, MM Docanto, SQ To, P Bukczynska, A Mant, N Ng, S Foroughi, LJK Graham, AM Haynes, S Azer, LE Lim, E Segelov, K Mahon, ID Davis, P Parente, C Pezaro, T Todenhöfer, N Sathianathen Show all
Translational Andrology and Urology | AME PUBLISHING COMPANY | Published : 2021
DOI: 10.21037/tau-20-1444
Abstract
Background: As potent systemic therapies transition earlier in the prostate cancer disease course, molecular biomarkers are needed to guide optimal treatment selection for metastatic hormone-sensitive prostate cancer (mHSPC). The value of whole blood RNA to detect candidate biomarkers in mHSPC remains largely undefined. Methods: In this cohort study, we used a previously optimised whole blood reverse transcription polymerase chain reaction assay to assess the prognostic utility [measured by seven-month undetectable prostate-specific antigen (PSA) and time to castration-resistance (TTCR)] of eight prostate cancer-associated gene transcripts in 43 mHSPC patients. Transcripts with statistically..
View full abstractGrants
Awarded by Cancer Council Tasmania
Funding Acknowledgements
We thank the patients and families for their participation in this study. We also thank Ms. Sophie Beck for providing statistical support during the manuscript revision process. Funding: The following authors formally acknowledge their respective sources of funding support: Edmond M. Kwan: NHMRC Postgraduate Scholarship, Monash University Postgraduate Publications Award; Heidi Fettke: Australian Government Research Training Program (RTP) Scholarship, Monash University Postgraduate Publications Award; Megan Crumbaker: Australian Government RTP Scholarship; Sarah Q. To: NHMRC CJ Martin Early Career Fellowship (APP1070112); Kate Mahon: Movember/Prostate Cancer Foundation of Australia Clinical Scientist Fellow; Ian D. Davis: NHMRC Practitioner Fellowship (APP1102604); Carmel Pezaro: Cancer Council Victoria Early Career Seed Grant; Lisa G. Horvath: Astellas Investigator-Initiated Grant, Cancer Institute NSW Translational Program Grant; Arun A. Azad: NHMRC Project Grant (GNT1098647), Victorian Cancer Agency Clinical Research Fellowship (CRF14009), Astellas Investigator-Initiated Grant.